Skip to main content

Client News

Rentschler Biopharma, Cell and Gene Therapy Catapult and Refeyn collaborate to improve process analytical technologies and AAV manufacturing for gene therapies

23rd August 2023

Destiny Pharma: Notice of Interim Results

23rd August 2023

ViGeneron Announces EMA Approval of Clinical Trial Application for VG901, a Gene Therapy to Treat Retinitis Pigmentosa

22nd August 2023

Mainz Biomed Announces Live Launch of ColoAlert® with testDNA Laboratory in Poland

22nd August 2023

Abivax secures up to EUR 150m from two structured debt financing transactions

22nd August 2023

Medigene AG Reports Second Quarter and Six Months 2023 Financial Results and Provides Corporate Update

17th August 2023

Mainz Biomed Announces Financial Half Year Results 2023 and Provides Corporate Update

15th August 2023

InflaRx Reports Second Quarter 2023 Financial Results & Operating Update

10th August 2023

Newron announces H1 2023 results and provides R&D update

4th August 2023

Mainz Biomed Announces Live Launch of ColoAlert® with Marylebone Laboratory in the United Kingdom

1st August 2023

Destiny Pharma: Publication of new data demonstrates significantly superior efficacy of XF-73 compared to a leading topical antibiotic against MRSA in skin infection models

31st July 2023

Tillotts Pharma and TVM Capital Life Science Announce Formation of Mage Biologics to Develop Innovative Oral Antibody Therapy for Ulcerative Colitis

20th July 2023

Destiny Pharma: Board changes including appointment of new CEO

19th July 2023

leon-nanodrugs appoints Dr. Hans Frickel as Chief Executive Officer

18th July 2023

Mainz Biomed Announces Collaboration with Fugene Genetics in Israel

18th July 2023

AATec Medical Announces its Launch with EUR 2.7 million in Seed Financing to Unlock the Therapeutic Potential of Alpha-1 Antitrypsin

17th July 2023

Rentschler Biopharma: Dr. Dominik Kugelstadt joins Rentschler Biopharma as Head of Clinical and Commercial Manufacturing, Laupheim

12th July 2023

Carbios announces the success of its capital increase with preferential subscription rights of approximately 141 million euros, the largest on Euronext Growth since 2015

11th July 2023

Abivax announces the appointment of June Lee, M.D. and Troy Ignelzi as Members of the Board of Directors

11th July 2023

Mallia Therapeutics Secures Seed Funding for its Novel Topical Treatment to Induce Hair Growth via Immune Modulation

11th July 2023

Numaferm and Zoetis Sign License Agreement to Collaborate on Developing and Producing Proteins and Peptides

6th July 2023

AiCuris Announces Strategic Shift to Focus Development and Commercialization of Anti-infectives for Immunocompromised Patients

6th July 2023

Secarna Pharmaceuticals publishes new preclinical data in The Journal of Immunology demonstrating potent therapeutic activity of LNAplus™ ASO targeting NLRP3 in highly debilitating autoinflammatory diseases

6th July 2023

Destiny Pharma: Positive Findings from Recent SAB Meeting

6th July 2023

Destiny Pharma: Business Update

29th June 2023

Mainz Biomed Secures up to $50m in New Funding

29th June 2023

Carbios incorporates its Purpose into company statutes and presents the results of its Special Meeting and Annual General Meeting of 22 June 2023

28th June 2023

InflaRx Appoints Dr. Camilla Chong as Chief Medical Officer

28th June 2023

Affluent Medical Presents Poster on First Successful Procedure with Epygon at the 2023 CSI Conference in Frankfurt

28th June 2023

Mainz Biomed to Attend ESMO World Congress on Gastrointestinal Cancer 2023 in Barcelona, Spain

28th June 2023

Imcyse joins CLAIMS, a European Health Initiative Project to Make Data-Driven Precision Medicine a Reality for Patients with Multiple Sclerosis

22nd June 2023

MIG Capital: MIG Capital co-leads seed investment in French space tech company Look Up Space

22nd June 2023

Carbios announces the launch of a rights issue totalling around €122 million, likely to be increased to around €141 million if the extension clause is fully exercised

22nd June 2023

InflaRx Announces Commercial Launch of Gohibic (vilobelimab) in the U.S. for the Treatment of Critically Ill COVID-19 Patients

21st June 2023

Mainz Biomed Expands into Romania through Partnership with Bioclinica

20th June 2023